Insmed (INSM) Expected to Post Quarterly Earnings on Thursday

Insmed (NASDAQ:INSM) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Insmed to post earnings of ($0.6939) per share and revenue of $393.7440 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. Insmed’s revenue was up 229.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.42) EPS. On average, analysts expect Insmed to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Insmed Stock Down 0.2%

Shares of Insmed stock opened at $98.45 on Tuesday. Insmed has a one year low of $90.39 and a one year high of $212.75. The company has a market cap of $21.34 billion, a P/E ratio of -17.12 and a beta of 0.78. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47. The firm has a fifty day moving average of $104.52 and a two-hundred day moving average of $130.30.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on INSM shares. HC Wainwright reiterated a “buy” rating and set a $220.00 price target on shares of Insmed in a research note on Monday, July 20th. Royal Bank Of Canada reduced their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Guggenheim reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Insmed in a report on Friday, July 10th. BMO Capital Markets began coverage on Insmed in a report on Monday, July 20th. They issued an “outperform” rating and a $192.00 price objective on the stock. Finally, Mizuho set a $192.00 target price on Insmed in a research report on Tuesday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $209.35.

Insider Activity at Insmed

In related news, CFO Sara Bonstein sold 2,404 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the sale, the chief financial officer owned 69,082 shares in the company, valued at $7,065,016.14. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the sale, the chief executive officer directly owned 259,058 shares in the company, valued at approximately $30,413,409.20. This represents a 3.97% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 54,590 shares of company stock valued at $5,793,738 over the last 90 days. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC boosted its stake in shares of Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. Raiffeisen Bank International AG purchased a new position in Insmed in the 4th quarter valued at approximately $32,000. Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new position in Insmed in the 4th quarter valued at approximately $49,000. Summit Securities Group LLC acquired a new position in Insmed during the fourth quarter worth $57,000. Finally, Transamerica Financial Advisors LLC raised its holdings in Insmed by 72.3% during the fourth quarter. Transamerica Financial Advisors LLC now owns 348 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 146 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.